American journal of translational research · 2026
Clinical efficacy of Conbercept combined with pars plana vitrectomy for proliferative diabetic retinopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Ying, Wang Mengran, Gao Jingzhao
Аннотация
OBJECTIVE: To evaluate the clinical efficacy of Conbercept combined with pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDR).
METHODS: A total of 118 PDR patients were retrospectively selected and allocated to a control group (n=52, undergoing PPV only) and an observation group (n=66, receiving preoperative intravitreal Conbercept combined with PPV) according their treatment regimen. Outcome measures included visual acuity improvement, best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), surgical indices (intraoperative electrocautery frequency, eyes with intraoperative bleeding, silicone oil usage, and iatrogenic retinal injury), preoperative aqueous humor cytokine levels, postoperative complications, and life quality.
RESULTS: Postoperative visual acuity was notably better in the observation group compared with the control group. Both groups showed significant reductions in BCVA, CRT, and IOP after surgery, with the observation group displaying even lower values. Intraoperative electrocautery frequency, eyes with bleeding, silicone oil usage, incidence of iatrogenic retinal injury, and preoperative aqueous humor cytokine levels were lower in the observation group compared with the control group. Moreover, the observation group also reported a lower overall complication rate and better postoperative quality of life.
CONCLUSION: Preoperative intravitreal Conbercept combined with PPV offers superior clinical benefits for PDR patients.
METHODS: A total of 118 PDR patients were retrospectively selected and allocated to a control group (n=52, undergoing PPV only) and an observation group (n=66, receiving preoperative intravitreal Conbercept combined with PPV) according their treatment regimen. Outcome measures included visual acuity improvement, best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), surgical indices (intraoperative electrocautery frequency, eyes with intraoperative bleeding, silicone oil usage, and iatrogenic retinal injury), preoperative aqueous humor cytokine levels, postoperative complications, and life quality.
RESULTS: Postoperative visual acuity was notably better in the observation group compared with the control group. Both groups showed significant reductions in BCVA, CRT, and IOP after surgery, with the observation group displaying even lower values. Intraoperative electrocautery frequency, eyes with bleeding, silicone oil usage, incidence of iatrogenic retinal injury, and preoperative aqueous humor cytokine levels were lower in the observation group compared with the control group. Moreover, the observation group also reported a lower overall complication rate and better postoperative quality of life.
CONCLUSION: Preoperative intravitreal Conbercept combined with PPV offers superior clinical benefits for PDR patients.